Physician profile
Bruce B Brown
NPI 1942280243
$8,515.21
in general payments reported to CMS, 2019-2025
31 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,157 · 2020: $542 · 2021: $1,098 · 2022: $1,236 · 2023: $1,553 · 2024: $1,478 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,481.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,892.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $925.71 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $742.97 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $661.74 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $592.96 | 2019-2025 | Jardiance |
| Pfizer INC. | $524.55 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $491.62 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $486.57 | 2019-2025 | Trintellix |
| Abbvie INC. | $331.06 | 2021-2025 | Ubrelvy, Vraylar, Skyrizi |
| Merck Sharp & Dohme LLC | $220.97 | 2019-2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Otsuka America Pharmaceutical, INC. | $213.90 | 2024-2025 | Rexulti |
| Abbott Laboratories | $203.20 | 2022-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $141.14 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $139.47 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $123.87 | 2019-2025 | Trelegy Ellipta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $113.31 | 2019 | |
| Janssen Biotech, INC. | $95.59 | 2024-2025 | Tremfya |
| Teva Pharmaceuticals USA, INC. | $87.77 | 2020-2025 | Austedo Xr |
| Dexcom, INC. | $85.07 | 2023-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $65.96 | 2022 | |
| Sanofi Pasteur INC. | $50.72 | 2019 | |
| Eisai INC. | $46.17 | 2021 | |
| Daiichi Sankyo INC. | $43.87 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $43.84 | 2023 | Quviviq |
| Exact Sciences Corporation | $38.59 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.61 | 2025 | Caplyta |
| Astellas Pharma US INC | $34.57 | 2024 | Veozah |
| Sumitomo Pharma America, INC. | $25.13 | 2023 | Gemtesa |
| Medtronic, INC. | $21.28 | 2025 | Interstim |
| Esperion Therapeutics, INC. | $20.59 | 2025 | Nexletol |
| Amarin Pharma, INC. | $16.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.